IL178672A - Imidazole derivatives used as tafia inhibitors - Google Patents

Imidazole derivatives used as tafia inhibitors

Info

Publication number
IL178672A
IL178672A IL178672A IL17867206A IL178672A IL 178672 A IL178672 A IL 178672A IL 178672 A IL178672 A IL 178672A IL 17867206 A IL17867206 A IL 17867206A IL 178672 A IL178672 A IL 178672A
Authority
IL
Israel
Prior art keywords
alkyl
twice
unsubstituted
imidazol
compound
Prior art date
Application number
IL178672A
Other languages
English (en)
Other versions
IL178672A0 (en
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34964308&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL178672(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of IL178672A0 publication Critical patent/IL178672A0/en
Publication of IL178672A publication Critical patent/IL178672A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/16Central respiratory analeptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL178672A 2004-04-22 2006-10-17 Imidazole derivatives used as tafia inhibitors IL178672A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004020186A DE102004020186A1 (de) 2004-04-22 2004-04-22 Heterocyclylessigsäuren als Inhibitoren von TAFla
PCT/EP2005/003630 WO2005105781A1 (de) 2004-04-22 2005-04-07 Imidazol-derivate als tafia-inhibitoren

Publications (2)

Publication Number Publication Date
IL178672A0 IL178672A0 (en) 2007-02-11
IL178672A true IL178672A (en) 2011-08-31

Family

ID=34964308

Family Applications (1)

Application Number Title Priority Date Filing Date
IL178672A IL178672A (en) 2004-04-22 2006-10-17 Imidazole derivatives used as tafia inhibitors

Country Status (34)

Country Link
EP (2) EP1864979B1 (https=)
JP (1) JP4939401B2 (https=)
KR (1) KR101162047B1 (https=)
CN (1) CN100572376C (https=)
AR (1) AR053302A1 (https=)
AT (2) ATE386737T1 (https=)
AU (1) AU2005238144B2 (https=)
BR (1) BRPI0510159A (https=)
CA (1) CA2563401C (https=)
CR (1) CR8650A (https=)
CY (1) CY1108087T1 (https=)
DE (2) DE102004020186A1 (https=)
DK (1) DK1740569T3 (https=)
EC (1) ECSP066941A (https=)
ES (1) ES2299026T3 (https=)
HR (1) HRP20080099T3 (https=)
IL (1) IL178672A (https=)
MA (1) MA28543B1 (https=)
MY (1) MY140903A (https=)
NI (1) NI200600217A (https=)
NO (1) NO20065320L (https=)
NZ (1) NZ550757A (https=)
PE (1) PE20060172A1 (https=)
PL (1) PL1740569T3 (https=)
PT (1) PT1740569E (https=)
RS (1) RS50553B (https=)
RU (1) RU2375356C2 (https=)
SI (1) SI1740569T1 (https=)
TN (1) TNSN06341A1 (https=)
TW (1) TWI359016B (https=)
UA (1) UA87306C2 (https=)
UY (1) UY28868A1 (https=)
WO (1) WO2005105781A1 (https=)
ZA (1) ZA200607668B (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009005516A (es) * 2006-12-06 2009-06-04 Sanofi Aventis Derivados de urea y de sulfamida en calidad de inhibidores de tafia.
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
WO2008100459A1 (en) * 2007-02-13 2008-08-21 Schering Corporation Derivatives and analogs of chroman as functionally selective alpha2c adrenoreceptor agonists
AU2008279447A1 (en) * 2007-07-19 2009-01-29 Metabolex, Inc. N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders
WO2009103432A2 (en) * 2008-02-21 2009-08-27 Sanofi-Aventis Covalently binding imaging probes
WO2009146802A1 (de) * 2008-06-06 2009-12-10 Sanofi-Aventis Makrocyclische harnstoff- und sulfamidderivate als inhibitoren von tafia
WO2010050525A1 (ja) 2008-10-29 2010-05-06 大正製薬株式会社 TAFIa阻害活性を有する化合物
RS52963B (sr) 2009-05-15 2014-02-28 Sanofi Postupak za dobijanje jedinjenja koje je korisno kao inhibitor tafia
FR2947266B1 (fr) * 2009-06-26 2011-06-17 Servier Lab Nouveaux derives d'acide 2-mercaptocyclopentanecarboxylique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP5909185B2 (ja) 2009-10-01 2016-04-26 シマベイ セラピューティクス, インコーポレーテッド 置換テトラゾール−1−イルフェノキシメチルチアゾール−2−イルピペリジニルピリミジン塩
BR112012023412A2 (pt) 2010-03-18 2018-05-08 Daiichi Sankyo Company, Limited composto, drogra farmacêutica, inibidor de tafia, promotor de fibrinólise, droga preventiva ou terapêutica, composição farmacêutica, e, uso de um composto.
EP2548871B1 (en) * 2010-03-18 2017-07-19 Daiichi Sankyo Company, Limited Cycloalkyl-substituted imidazole derivative
EP2638016B1 (en) * 2010-11-11 2014-10-01 Sanofi Process for the preparation of 3-(6-amino-pyridin-3yl)-2-acrylic acid derivatives
EP2782575B1 (en) 2011-11-25 2016-04-20 Sanofi Crystalline salts of r)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1h-imidazol-4-yl)-propionic acid
WO2013076179A1 (en) 2011-11-25 2013-05-30 Sanofi Sodium salt of (r)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1h-imidazol-4-yl)-propionic acid
WO2013076177A1 (de) 2011-11-25 2013-05-30 Sanofi Salz von (r)-3-(6-amino-pyridin-3-yl)-2-(1-cyclohexyl-1h-imidazol-4-yl)- propionsäureethylester
EP3184095A1 (en) 2013-05-23 2017-06-28 IP Gesellschaft für Management mbH Administration units comprising polymorph 1 of 2-(2-methylamino-pyrimidin-4-yl]-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide
KR20160018557A (ko) 2013-06-10 2016-02-17 사노피 TAFIa의 저해제로서의 마크로사이클릭 우레아 유도체, 이의 제법 및 의약품으로서의 이의 용도
US20190117624A1 (en) 2016-03-29 2019-04-25 Daiichi Sankyo Company, Limited Therapeutic agent for inflammatory bowel diseases
AU2017305392A1 (en) 2016-08-03 2019-02-21 Cymabay Therapeutics, Inc. Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2292262T3 (es) * 1998-12-24 2008-03-01 Astellas Pharma Inc. Compuestos de imidazol y su uso medicinal.
WO2003013526A1 (en) * 2001-08-08 2003-02-20 Merck & Co. Inc. Anticoagulant compounds
BR0307033A (pt) 2002-01-22 2004-12-07 Pfizer ácidos 3-(imidazolil)-2-aminopropanóicos para o uso como inibidores tafi-a para o tratamento de doenças trombóticas

Also Published As

Publication number Publication date
PL1740569T3 (pl) 2008-07-31
HK1101823A1 (zh) 2007-10-26
KR20070007346A (ko) 2007-01-15
SI1740569T1 (sl) 2008-06-30
BRPI0510159A (pt) 2007-10-02
DE502005002927D1 (de) 2008-04-03
ZA200607668B (en) 2008-03-26
HRP20080099T3 (en) 2008-03-31
EP1864979B1 (de) 2011-09-07
KR101162047B1 (ko) 2012-07-04
EP1740569B1 (de) 2008-02-20
AR053302A1 (es) 2007-05-02
CN1950357A (zh) 2007-04-18
EP1864979A1 (de) 2007-12-12
NZ550757A (en) 2010-06-25
PT1740569E (pt) 2008-03-31
IL178672A0 (en) 2007-02-11
TWI359016B (en) 2012-03-01
CA2563401A1 (en) 2005-11-10
ECSP066941A (es) 2006-12-20
ATE386737T1 (de) 2008-03-15
DE102004020186A1 (de) 2005-11-17
UY28868A1 (es) 2005-11-30
NI200600217A (es) 2008-06-17
WO2005105781A1 (de) 2005-11-10
RU2375356C2 (ru) 2009-12-10
NO20065320L (no) 2007-01-12
CN100572376C (zh) 2009-12-23
CY1108087T1 (el) 2014-02-12
DK1740569T3 (da) 2008-06-02
RU2006141246A (ru) 2008-06-10
ES2299026T3 (es) 2008-05-16
TNSN06341A1 (en) 2008-02-22
JP4939401B2 (ja) 2012-05-23
MA28543B1 (fr) 2007-04-03
AU2005238144B2 (en) 2010-08-26
RS50553B (sr) 2010-05-07
CR8650A (es) 2007-12-04
AU2005238144A1 (en) 2005-11-10
UA87306C2 (en) 2009-07-10
ATE523505T1 (de) 2011-09-15
MY140903A (en) 2010-01-29
JP2007533672A (ja) 2007-11-22
TW200602325A (en) 2006-01-16
CA2563401C (en) 2012-08-07
PE20060172A1 (es) 2006-03-31
EP1740569A1 (de) 2007-01-10

Similar Documents

Publication Publication Date Title
CA2563401C (en) Imidazole derivatives used as tafia inhibitors
JP4585448B2 (ja) 第Xa因子阻害剤としてのピラゾール−誘導体
JP4861306B2 (ja) Xa因子阻害剤としてのピロール誘導体
WO2003013526A1 (en) Anticoagulant compounds
US8044208B2 (en) Imidazole derivatives as inhibitors of TAFIa
WO2000039117A1 (en) HETEROROAROMATIC AMIDES AS INHIBITOR OF FACTOR Xa
EP1358178A2 (en) Sulfonamide lactam inhibitors of factor xa
US8710232B2 (en) Imidazole derivatives used as TAFIa inhibitors
DK2104497T3 (en) SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIA
JP2006528941A (ja) 第Xa因子阻害剤としてのトリアゾール誘導体
JP4504820B2 (ja) Xa因子阻害剤としてのイミダゾール誘導体
JP4658940B2 (ja) 第Xa因子阻害剤としてのベンゾイミダゾール誘導体
MXPA06011067A (en) Imidazole derivatives used as tafia inhibitors
HK1101823B (en) Imidazole derivatives used as tafia inhibitors
JP2008501746A (ja) ベンズイミダゾール、それらの製造方法、及び医薬としての使用
JP2006527728A (ja) Xa因子の阻害剤としての2−ピロリドン誘導体およびその使用
JPWO2000078747A1 (ja) アシルヒドラジン誘導体、その製造法及び用途
HK1120512A (en) 2-hydroxy-3-heteroarylindole derivatives as gsk3 inhibitors
AU2002248391A1 (en) Sulfonamide lactam inhibitors of factor XA
JPWO1999033805A1 (ja) 環状アミノ基を有する芳香族化合物またはその塩
KR20060136457A (ko) 인자 Xa 억제제로서의 피롤-유도체

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees